ArticlePediatric surgery international2025
Human induced pluripotent stem cell-derived bioengineered skeletal muscle progenitor sheet.
Article in Pediatric surgery international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNeonates with congenital diaphragmatic hernia (CDH) often require surgical closure of the large diaphragmatic defect with a patch; however, artificial materials are associated with complications such as foreign body reaction, infection, and recurrence. Regenerative medicine is a promising alternative for CDH patch repair, particularly through the application of stem cells and tissue engineering techniques. Despite recent research focusing on amniotic fluid stem cells, no research has focused on the use of human induced pluripotent stem cells (iPSCs) to create a skeletal muscle sheet for diaphragmatic replacement. DAPT and SB431542 (SB) have been described to promote hypertrophy and fusion of myoblasts lines for myotube formation. In this study, we generated an iPSC-derived skeletal muscle progenitor sheet and evaluated its viability for diaphragmatic replacement in CDH.
methodsHuman iPSCs (HiPS-RIKEN-2F) were cultured in StemFit AK02N medium on iMatrix511-coated dishes and differentiated into skeletal myogenic progenitor cells using a stepwise induction protocol with CHIR99021 and FGF2. After 35 days, cells were transferred to α-MEM medium containing 2% horse serum (HS) to create a monolayer skeletal muscle progenitor sheet in a temperature-responsive culture dish. To evaluate myotube formation from myogenic progenitor cells under various conditions using compounds; DAPT, SB, and DAPT + SB combination, myosin heavy chain expression was assessed by immunofluorescence staining.
resultsUsing α-MEM medium containing 2% HS, we could create a monolayer skeletal muscle progenitor sheet derived from human iPSCs. Compared to individual treatments, the most effective myotube formation was observed using a DAPT + SB combination.
conclusionsWe created, for the first time, bioengineered skeletal muscle progenitor sheet derived from human iPSCs. Combinatorial treatment with DAPT and SB was the most effective to promote myotube formation in the bioengineered sheet. iPSC-derived skeletal muscle progenitor sheets may be useful for tissue-engineered diaphragmatic replacement in the future.
Indexed as
Identifiers
41269327What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.